FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2314193179> ?p ?o ?g. }

• W2314193179 endingPage "1580" @default.
• W2314193179 startingPage "1580" @default.
• W2314193179 abstract "Muscle-related statin intolerance is reported by 5% to 20% of patients.To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab.Two-stage randomized clinical trial including 511 adult patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) levels and history of intolerance to 2 or more statins enrolled in 2013 and 2014 globally. Phase A used a 24-week crossover procedure with atorvastatin or placebo to identify patients having symptoms only with atorvastatin but not placebo. In phase B, after a 2-week washout, patients were randomized to ezetimibe or evolocumab for 24 weeks.Phase A: atorvastatin (20 mg) vs placebo. Phase B: randomization 2:1 to subcutaneous evolocumab (420 mg monthly) or oral ezetimibe (10 mg daily).Coprimary end points were the mean percent change in LDL-C level from baseline to the mean of weeks 22 and 24 levels and from baseline to week 24 levels.Of the 491 patients who entered phase A (mean age, 60.7 [SD, 10.2] years; 246 women [50.1%]; 170 with coronary heart disease [34.6%]; entry mean LDL-C level, 212.3 [SD, 67.9] mg/dL), muscle symptoms occurred in 209 of 491 (42.6%) while taking atorvastatin but not while taking placebo. Of these, 199 entered phase B, along with 19 who proceeded directly to phase B for elevated creatine kinase (N = 218, with 73 randomized to ezetimibe and 145 to evolocumab; entry mean LDL-C level, 219.9 [SD, 72] mg/dL). For the mean of weeks 22 and 24, LDL-C level with ezetimibe was 183.0 mg/dL; mean percent LDL-C change, -16.7% (95% CI, -20.5% to -12.9%), absolute change, -31.0 mg/dL and with evolocumab was 103.6 mg/dL; mean percent change, -54.5% (95% CI, -57.2% to -51.8%); absolute change, -106.8 mg/dL (P < .001). LDL-C level at week 24 with ezetimibe was 181.5 mg/dL; mean percent change, -16.7% (95% CI, -20.8% to -12.5%); absolute change, -31.2 mg/dL and with evolocumab was 104.1 mg/dL; mean percent change, -52.8% (95% CI, -55.8% to -49.8%); absolute change, -102.9 mg/dL (P < .001). For the mean of weeks 22 and 24, between-group difference in LDL-C was -37.8%; absolute difference, -75.8 mg/dL. For week 24, between-group difference in LDL-C was -36.1%; absolute difference, -71.7 mg/dL. Muscle symptoms were reported in 28.8% of ezetimibe-treated patients and 20.7% of evolocumab-treated patients (log-rank P = .17). Active study drug was stopped for muscle symptoms in 5 of 73 ezetimibe-treated patients (6.8%) and 1 of 145 evolocumab-treated patients (0.7%).Among patients with statin intolerance related to muscle-related adverse effects, the use of evolocumab compared with ezetimibe resulted in a significantly greater reduction in LDL-C levels after 24 weeks. Further studies are needed to assess long-term efficacy and safety.clinicaltrials.gov Identifier: NCT01984424." @default.
• W2314193179 created "2016-06-24" @default.
• W2314193179 creator A5017005943 @default.
• W2314193179 creator A5020693718 @default.
• W2314193179 creator A5025538949 @default.
• W2314193179 creator A5039985378 @default.
• W2314193179 creator A5040589473 @default.
• W2314193179 creator A5043161884 @default.
• W2314193179 creator A5049272753 @default.
• W2314193179 creator A5052604218 @default.
• W2314193179 creator A5055596681 @default.
• W2314193179 creator A5060465607 @default.
• W2314193179 creator A5063541240 @default.
• W2314193179 creator A5067039078 @default.
• W2314193179 creator A5070060204 @default.
• W2314193179 creator A5072095037 @default.
• W2314193179 creator A5081269201 @default.
• W2314193179 creator A5081557648 @default.
• W2314193179 creator A5086317157 @default.
• W2314193179 creator A5088378588 @default.
• W2314193179 date "2016-04-19" @default.
• W2314193179 modified "2023-10-16" @default.
• W2314193179 title "Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance" @default.
• W2314193179 cites W121888607 @default.
• W2314193179 cites W1423581981 @default.
• W2314193179 cites W1975636428 @default.
• W2314193179 cites W1980979503 @default.
• W2314193179 cites W1992862300 @default.
• W2314193179 cites W1995622206 @default.
• W2314193179 cites W1998569580 @default.
• W2314193179 cites W2001328643 @default.
• W2314193179 cites W2014561045 @default.
• W2314193179 cites W2019071303 @default.
• W2314193179 cites W2106285889 @default.
• W2314193179 cites W2115012618 @default.
• W2314193179 cites W2134159541 @default.
• W2314193179 cites W2477872031 @default.
• W2314193179 doi "https://doi.org/10.1001/jama.2016.3608" @default.
• W2314193179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27039291" @default.
• W2314193179 hasPublicationYear "2016" @default.
• W2314193179 type Work @default.
• W2314193179 sameAs 2314193179 @default.
• W2314193179 citedByCount "395" @default.
• W2314193179 countsByYear W23141931792016 @default.
• W2314193179 countsByYear W23141931792017 @default.
• W2314193179 countsByYear W23141931792018 @default.
• W2314193179 countsByYear W23141931792019 @default.
• W2314193179 countsByYear W23141931792020 @default.
• W2314193179 countsByYear W23141931792021 @default.
• W2314193179 countsByYear W23141931792022 @default.
• W2314193179 countsByYear W23141931792023 @default.
• W2314193179 crossrefType "journal-article" @default.
• W2314193179 hasAuthorship W2314193179A5017005943 @default.
• W2314193179 hasAuthorship W2314193179A5020693718 @default.
• W2314193179 hasAuthorship W2314193179A5025538949 @default.
• W2314193179 hasAuthorship W2314193179A5039985378 @default.
• W2314193179 hasAuthorship W2314193179A5040589473 @default.
• W2314193179 hasAuthorship W2314193179A5043161884 @default.
• W2314193179 hasAuthorship W2314193179A5049272753 @default.
• W2314193179 hasAuthorship W2314193179A5052604218 @default.
• W2314193179 hasAuthorship W2314193179A5055596681 @default.
• W2314193179 hasAuthorship W2314193179A5060465607 @default.
• W2314193179 hasAuthorship W2314193179A5063541240 @default.
• W2314193179 hasAuthorship W2314193179A5067039078 @default.
• W2314193179 hasAuthorship W2314193179A5070060204 @default.
• W2314193179 hasAuthorship W2314193179A5072095037 @default.
• W2314193179 hasAuthorship W2314193179A5081269201 @default.
• W2314193179 hasAuthorship W2314193179A5081557648 @default.
• W2314193179 hasAuthorship W2314193179A5086317157 @default.
• W2314193179 hasAuthorship W2314193179A5088378588 @default.
• W2314193179 hasBestOaLocation W23141931791 @default.
• W2314193179 hasConcept C126322002 @default.
• W2314193179 hasConcept C134018914 @default.
• W2314193179 hasConcept C142724271 @default.
• W2314193179 hasConcept C197934379 @default.
• W2314193179 hasConcept C204787440 @default.
• W2314193179 hasConcept C27081682 @default.
• W2314193179 hasConcept C2776839432 @default.
• W2314193179 hasConcept C2777482532 @default.
• W2314193179 hasConcept C2778114629 @default.
• W2314193179 hasConcept C2778163477 @default.
• W2314193179 hasConcept C2778375690 @default.
• W2314193179 hasConcept C2778657065 @default.
• W2314193179 hasConcept C2780072125 @default.
• W2314193179 hasConcept C2780745583 @default.
• W2314193179 hasConcept C2780948078 @default.
• W2314193179 hasConcept C43554185 @default.
• W2314193179 hasConcept C71924100 @default.
• W2314193179 hasConcept C90924648 @default.
• W2314193179 hasConceptScore W2314193179C126322002 @default.
• W2314193179 hasConceptScore W2314193179C134018914 @default.
• W2314193179 hasConceptScore W2314193179C142724271 @default.
• W2314193179 hasConceptScore W2314193179C197934379 @default.
• W2314193179 hasConceptScore W2314193179C204787440 @default.
• W2314193179 hasConceptScore W2314193179C27081682 @default.
• W2314193179 hasConceptScore W2314193179C2776839432 @default.
• W2314193179 hasConceptScore W2314193179C2777482532 @default.
• W2314193179 hasConceptScore W2314193179C2778114629 @default.

• next